150
Participants
Start Date
October 31, 2003
Primary Completion Date
March 31, 2009
Study Completion Date
October 31, 2009
Docetaxel
"For Arm 1: 30mg/m2 mg IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression combined with carboplatin~For Arm 2: 30mg/m2 IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression followed by carboplatin"
Carboplatin
"Arm 1: AUC 6 IV on Days 1 and 8, repeated every 21 days for 6 cycles or until disease progression, combined with docetaxel.~Arm 2: AUC 6 IV every 21 days for 6 cycles or until disease progression, following six cycles of treatment with docetaxel"
Columbia University College of Physicians and Surg, New York
Western Pennsylvania Hospital, Pittsburgh
PA Hematology/Oncology Associates, Philadelphia
Forsyth Regional Cancer Center, Winston-Salem
Carolinas Medical Center/Gyn Oncology Department, Charlotte
Hope: A Woman's Cancer Center, Asheville
MUSC-Div of Gyn/Oncology, Charleston
Florida Hospital/Gyn/Onc Department, Orlando
Jupiter Medical Center-Gynecology Oncology and Gynecology, Jupiter
Florida Gynecologic Oncology, Fort Myers
The West Cancer Clinic, Memphis
University of Iowa, Iowa City
Hematology-Onc. Assoc. of The Quad Cities, Bettendorf
Gynecologic Oncology and Surgery, Oklahoma City
Southwest Regional Cancer Center, Austin
Franklin Square Hospital Center/MedStar Health-Section of Hematology/Oncology, Baltimore
Cancer Center at Hackensack, Hackensack
University of North Carolina/ Division of Gyn Oncology, Chapel Hill
Duke University/Division of Gynecologic Oncology, Durham
Lead Sponsor
Collaborators (1)
Aventis Pharmaceuticals
INDUSTRY
Duke University
OTHER